Hepatic Encephalopathy Treatment Escalation

Protect the airway when depressed consciousness or loss of protective reflexes creates aspiration risk. Airway protection is specifically emphasized in decompensated cirrhosis admissions, and overt hepatic encephalopathy can range from subtle neuropsychiatric impairment to profound coma. BMJ+1BMJDecompensated cirrhosis: an update of the BSG/BASL admission ...ScienceDirectAnalysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy

Do not attribute acute altered mental status automatically to hepatic encephalopathy. Reassess for intracranial hematoma or cerebrovascular accident, encephalitis, thyroid dysfunction, hypoglycemia, hypoxia, hypercapnia, sedative, narcotic, psychotropic drug, or alcohol intoxication, and acid-base disturbance; each may mimic, coexist with, or worsen encephalopathy and requires cause-directed management. accessdata fdaaccessdata fda[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEW

Once airway safety and immediate competing emergencies have been addressed, begin treatment for the overt episode rather than waiting for every precipitant study to return. Guidelines summarized in long-term management evidence recommend active treatment whether the episode is spontaneous or precipitated. PubMedPubMedLong-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMC

Search systematically for infection and gastrointestinal hemorrhage, particularly spontaneous bacterial peritonitis, fever or sepsis, anemia from acute or chronic gastrointestinal bleeding, and hypotension or hypovolemia from bleeding, shock, peripheral vasodilation, overdiuresis, diarrhea, vomiting, or paracentesis. These conditions are recognized concurrent causes and precipitants of encephalopathy. accessdata fdaaccessdata fda[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEW

Correct constipation, dehydration, acid-base disorders, hyponatremia, hypokalemia, uremia or azotemia, and medication-related neurodepression. Protein restriction is no longer recommended as a response to encephalopathy; excessive protein intake is listed as a potential precipitant, but restriction is not recommended. accessdata fdaaccessdata fda[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEW

When encephalopathy persists despite correction of an identified precipitant and standard therapy, repeat the medication and exposure review, reassess volume status and renal function, and revisit alternative neurologic, metabolic, and respiratory diagnoses. This approach is particularly important after surgery, when several listed drivers may coexist. accessdata fdaaccessdata fda[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEW

Use lactulose as first-choice therapy for episodic hepatic encephalopathy. Nonabsorbable disaccharides, including lactulose and lactitol, are recommended as first-line treatment, and guideline summaries identify lactulose as the first choice for both episodic treatment and prevention of recurrent episodes after the initial episode. Cochrane+1CochraneNon‐absorbable disaccharides versus placebo/no intervention and ...PubMedLong-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMC

The practical escalation problem is usually inadequate delivery or titration rather than a need to abandon lactulose immediately. Patients receiving chronic lactulose should be counseled to titrate treatment to their target number of bowel movements per day; inadequate titration has been identified as a common contributor to preventable readmission. BMJBMJHepatic encephalopathy - Prevention | BMJ Best Practice

If recurrent episodes occur on lactulose, first establish whether the patient is taking and titrating the drug consistently and whether constipation or another precipitant is still present. Inadequate adherence is a major limitation of lactulose therapy. BMJ+1BMJHepatic encephalopathy - Prevention | BMJ Best PracticeScienceDirectAnalysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy

Add rifaximin to lactulose for secondary prophylaxis after recurrent overt hepatic encephalopathy. AASLD and EASL guidance summarized in the available evidence recommends rifaximin as an effective add-on after the second overt episode, while another guideline summary describes add-on treatment following at least one overt episode within 6 months of the first in patients with episodic disease. BMJ+1BMJHepatic encephalopathy - Prevention | BMJ Best PracticePubMedLong-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMC

Use rifaximin 550 mg orally twice daily. It is often started after acute episode resolution and may be initiated during the hospitalization; its approved use is prevention of recurrent hepatic encephalopathy. aasldaasldWhy do we use Lactulose and Rifaximin for Hepatic Encephalopathy?

Do not substitute rifaximin for correction of an active precipitant. Recurrent encephalopathy despite lactulose should prompt both rifaximin addition and a check for infection, bleeding, constipation, dehydration, electrolyte disturbance, renal dysfunction, or psychoactive drug exposure. accessdata fda+1accessdata fda[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEWPubMedLong-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMC

For lactulose intolerance, ineffectiveness, or adherence failure, rifaximin monotherapy has been proposed in emerging evidence, but the review characterizes this strategy as requiring further research. Combination therapy remains the better-supported escalation approach for recurrence. PubMedPubMedLong-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMC

When mental status fails to improve after lactulose-based treatment and precipitant correction, reassess whether the diagnosis is correct and whether a trigger remains untreated. Intracranial pathology, encephalitis, thyroid disease, hypoglycemia, hypoxia, hypercapnia, intoxication, acid-base disorders, renal dysfunction, and electrolyte abnormalities remain competing or concurrent explanations. accessdata fdaaccessdata fda[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEW

Consider portosystemic shunting as a major structural branch in recurrent or difficult-to-control disease. Hepatic encephalopathy is a syndrome associated with portosystemic venous shunting with or without intrinsic liver disease, and it is a common complication after transjugular intrahepatic portosystemic shunt creation. ScienceDirect+1ScienceDirectAnalysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathypubs rsnaTIPS-related Hepatic Encephalopathy: Management Options with ...

Reserve alternative adjunctive approaches for patients not responsive to conventional therapy. Intravenous L-ornithine L-aspartate and oral branched-chain amino acids are described as alternative or additional agents in this setting, whereas probiotics remain investigational for secondary prevention because a placebo-controlled trial showed fewer breakthrough episodes without a statistically significant difference. NEJM+1NEJMProbiotics for Secondary Prevention of Hepatic Encephalopathy? | NEJM ClinicianPubMedLong-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMC

After overt hepatic encephalopathy resolves, continue secondary prophylaxis rather than stopping therapy at discharge. Lactulose is recommended after an initial episode, and rifaximin is added for recurrent disease; recurrence on lactulose monotherapy has been described as a 40% cumulative risk within 6 months of an initial overt episode. PubMed+1PubMedLong-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMCaasldWhy do we use Lactulose and Rifaximin for Hepatic Encephalopathy?

Give patients and caregivers explicit lactulose titration instructions and confirm the plan before discharge. Preventable readmission has been linked to failure to titrate lactulose adequately, while poor adherence remains a major limitation of lactulose therapy. BMJ+1BMJHepatic encephalopathy - Prevention | BMJ Best PracticeScienceDirectAnalysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy

Reassess whether prophylactic therapy can ever be withdrawn only when precipitating factors, such as infection and variceal bleeding, have been well controlled. Otherwise, continue prophylaxis and review for recurrent triggers at every breakthrough event. PubMedPubMedLong-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence - PMC